| Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ... Clinical Cancer Research 24 (6), 1326-1336, 2018 | 343 | 2018 |
| Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu British journal of cancer 121 (10), 809-818, 2019 | 279 | 2019 |
| Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer I Tekedereli, SN Alpay, CDJ Tavares, ZE Cobanoglu, TS Kaoud, I Sahin, ... PloS one 7 (7), e41171, 2012 | 140 | 2012 |
| Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? IH Sahin, G Askan, ZI Hu, EM O’Reilly Annals of Oncology 28 (12), 2950-2961, 2017 | 111 | 2017 |
| Pancreatic cancer microenvironment: a current dilemma B Uzunparmak, IH Sahin Clinical and translational medicine 8 (1), 2, 2019 | 92 | 2019 |
| Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature IH Sahin, SMA Kazmi, JT Yorio, NA Bhadkamkar, BK Kee, CR Garrett Journal of Cancer 4 (4), 320, 2013 | 86 | 2013 |
| Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma AO Kaseb, M Shama, IH Sahin, A Nooka, HM Hassabo, JN Vauthey, ... Oncology 85 (4), 197-203, 2013 | 83 | 2013 |
| Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science IH Sahin, MM Hassan, CR Garrett Cancer letters 345 (2), 249-257, 2014 | 80 | 2014 |
| Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches IH Sahin, MA Lowery, ZK Stadler, E Salo-Mullen, CA Iacobuzio-Donahue, ... Expert review of gastroenterology & hepatology 10 (8), 893-905, 2016 | 59 | 2016 |
| Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy IH Sahin, CA Iacobuzio-Donahue, EM O’Reilly Expert opinion on therapeutic targets 20 (3), 341-359, 2016 | 51 | 2016 |
| Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior IH Sahin, H Elias, JF Chou, M Capanu, EM O’Reilly BMC cancer 18, 1-8, 2018 | 49 | 2018 |
| Precision medicine for metastatic colorectal cancer: an evolving era I Guler, G Askan, J Klostergaard, IH Sahin Expert review of gastroenterology & hepatology 13 (10), 919-931, 2019 | 43 | 2019 |
| Association of diabetes and perineural invasion in pancreatic cancer IH Sahin, MA Shama, M Tanaka, JL Abbruzzese, SA Curley, M Hassan, ... Cancer medicine 1 (3), 357-362, 2012 | 42 | 2012 |
| A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer RD Kim, BP Kovari, M Martinez, H Xie, IH Sahin, R Mehta, J Strosberg, ... European Journal of Cancer 169, 93-102, 2022 | 38 | 2022 |
| Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma G Askan, IH Sahin, JF Chou, A Yavas, M Capanu, CA Iacobuzio-Donahue, ... BMC cancer 21, 1-11, 2021 | 32 | 2021 |
| Immune‐related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration‐approved indications for … S Das, KK Ciombor, S Haraldsdottir, Y Pumpalova, IH Sahin, G Pineda, ... The oncologist 25 (8), 669-679, 2020 | 30 | 2020 |
| Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues IH Sahin, KK Ciombor, LA Diaz, J Yu, R Kim American Society of Clinical Oncology Educational Book 42, 242-253, 2022 | 27 | 2022 |
| Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer IH Sahin, S Goyal, Y Pumpalova, MB Sonbol, S Das, S Haraldsdottir, ... The Oncologist 26 (8), 668-675, 2021 | 25 | 2021 |
| BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues IH Sahin, J Klostergaard JCO Oncology Practice 17 (12), 723-730, 2021 | 24 | 2021 |
| CD44 as a drug delivery target in human cancers: where are we now? IH Sahin, J Klostergaard Expert Opinion on Therapeutic Targets 19 (12), 1587-1591, 2015 | 24 | 2015 |
